RxDoctor Payments Data

Suzanne Crocker

Family · Huntsville, ALNPI 1811385057

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 45 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scilex Pharmaceuticals Inc.$328
  • Collegium Pharmaceutical, Inc.$280
  • Novo Nordisk$118
  • Averitas Pharma Inc.$110
  • Almatica Pharma LLC$91
  • AbbVie$74
  • plus $148 from 8 others

What the payments were for

  • Food & beverage$1,148100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,148 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$32,846
Medicare patients
136
Services billed
609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen636$13,619
LinzessLinaclotide17$8,992
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen306$7,284
Tizanidine Hcl317$3,359
Tramadol Hcl ErTramadol Hcl32$1,845
Baclofen182$1,765
Lidocaine13$1,458
Naloxone Hcl18$1,227
Duloxetine Hcl61$815
Oxycodone Hcl21$539
Lactulose24$536
Diclofenac Sodium14$467
Celecoxib41$434
Trazodone Hcl68$316
Gabapentin36$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$74$8,99217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.

Other family in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →